Skip to main content

Market Overview

UPDATE: Nomura Raises Price Target On BioMarin Pharmaceutical On Positive Preliminary BMN-190 Data


In a report published Wednesday, Nomura analyst Ian Somaiya reiterated a Buy rating on BioMarin Pharmaceutical (NASDAQ: BMRN), and raised the price target from $114.00 to $116.00.

In the report, Nomura noted, “We are increasing our TP on BMRN to $116 following the release of positive preliminary Phase I/II data from BMN-190, in development for the treatment of CLN2, a late infantile form of Batten Disease. In the study, all nine patients with at least six months of treatment demonstrated evidence of disease stabilization for motor and language function versus natural history controls. These data increase our confidence that full Phase I/II results will be positive when the trial reads out in 4Q15 and support our higher probability of success estimate of 67% (was 20%). We continue to see the next 12-15 months as a data rich period for BioMarin, with five mid- to late-stage pipeline readouts that we believe could provide visibility into >$2bn in potential revenues and support our belief that BioMarin's top line could double over the next four years. BioMarin remains our top mid-cap pick for 2015.”

BioMarin Pharmaceutical closed on Tuesday at $97.13.

Latest Ratings for BMRN

Apr 2021Morgan StanleyMaintainsEqual-Weight
Mar 2021Canaccord GenuityMaintainsBuy
Mar 2021Evercore ISI GroupUpgradesIn-LineOutperform

View More Analyst Ratings for BMRN
View the Latest Analyst Ratings


Related Articles (BMRN)

View Comments and Join the Discussion!

Posted-In: Ian Somaiya NomuraAnalyst Color Price Target Analyst Ratings

Latest Ratings

VZIOWells FargoInitiates Coverage On31.0
OMWells FargoInitiates Coverage On63.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at